HIGH SCHOOL EDITION
Journal of Student Research
Volume 12 Issue 3 (2023)

Prevention of Drug-resistant Tuberculosis

Aarav Sinha[1], Dr. Rajagopal Appavu[#] and Jothsna Kethar[#]

[1]Panther Creek Highschool, Texas
[#]Advisor

ABSTRACT

Drug-resistant tuberculosis (TB) poses a significant global health challenge, affecting millions worldwide. Annually, around half a million individuals develop drug-resistant TB, underscoring the urgency of addressing this issue. Treating drug-resistant TB is complex and lengthy, lasting up to two years for a cure. Thus, prevention is the most effective approach to reducing its incidence and prevalence. This paper explores various aspects of drug-resistant TB, providing a holistic understanding of the current knowledge. Firstly, it examines the historical context of drug resistance in TB, tracing its origins and evolution, yielding insights into present challenges. Additionally, the paper elucidates current treatment options, emphasizing the need for a multi-drug approach. The efficacy, limitations, and side effects of these regimens are evaluated, offering a comprehensive overview. Prevention is paramount, and the paper emphasizes its critical importance. Preventive measures such as isoniazid therapy and vaccinations are scrutinized, assessing their efficacy in reducing drug-resistant TB's spread. Global efforts to combat drug-resistant TB, notably the "End TB" strategy by WHO, are highlighted. This plan aims to eradicate TB in all forms, including drug-resistant strains. Understanding its components and objectives provides insight into collective global efforts. Based on historical analysis, current treatment options, prevention strategies, and global efforts, the paper concludes by presenting recommendations for future research and interventions. Ongoing scientific inquiry and innovation are essential for developing more effective treatments, preventive measures, and diagnostics. Furthermore, comprehensive public health interventions encompassing education, awareness campaigns, and strengthened healthcare systems are vital in preventing the spread of drug-resistant TB.

Introduction

Antibiotics are limited resources, and their misuse has led to antibiotic resistance, diminishing their effectiveness within a short span of time after their introduction. The World Health Organization (WHO) recognizes antibiotic resistance as a global security threat that impacts various aspects, including global health, food security, and development. In fact, it is regarded as important as terrorism and climate change. Annually, 700,000 people lose their lives due to resistant infections, and if the current trend continues, the Wellcome Trust and the British Government predict that 10 million people will die in 2050 due to antimicrobial resistance (AMR). Among these deaths, 230,000 occur as a result of multidrug-resistant tuberculosis (MDR-TB). Recognizing the severity of the situation, the WHO has prioritized MDR-TB as a global concern, urging investments in new drugs. Furthermore, in response to member states' request, the WHO created a priority list of other antibiotic-resistant bacteria to support research and development of effective drugs in 2016.

Tuberculosis (TB), caused by Mycobacterium tuberculosis, is a highly infectious disease posing a significant global health challenge. Annually, approximately 10 million people contract TB, resulting in 1.5 million deaths. This disease is particularly prevalent in low- and middle-income countries, where 95% of TB-related fatalities occur.
Drug-resistant TB, which does not respond to standard first-line drugs, presents a substantial public health dilemma. Around half a million people develop drug-resistant TB each year. Treating drug-resistant TB is a complex and lengthy

process, often taking up to two years to cure a patient. In addition to the treatment challenges, drug-resistant TB is costlier to treat compared to drug-susceptible TB, placing a significant burden on healthcare systems and individuals. To address the escalating issue of drug-resistant TB, prevention emerges as the most effective approach to reducing its incidence. This research paper aims to provide an overview of the current understanding of drug-resistant TB prevention, encompassing topics such as the utilization of preventive therapies, the role of infection control, and the significance of strengthening health systems. By exploring these aspects, this paper seeks to contribute to the development of strategies and interventions that can effectively combat drug-resistant TB and mitigate its impact on public health.

Exploring Drug-resistant tuberculosis

History of Antibiotic Resistance in TB

For millennia, tuberculosis (TB) has been one of the most devastating diseases to afflict humanity, often referred to as "consumption" or phthisis. Until the late 18th century, a diagnosis of TB was essentially a death sentence, as effective treatments were non-existent. However, a significant breakthrough came in 1882 when Dr. Robert Koch identified Mycobacterium tuberculosis as the causal agent of the disease. This discovery paved the way for improved therapies, and soon after, the sanatorium movement gained momentum in Europe and the United States, focusing on isolating TB patients in specialized facilities for treatment and prevention.

Despite these advancements, it took several more decades before the discovery of antibiotics sparked a genuine revolution in TB chemotherapy. In what became known as the "Golden Era of Antibiotics" spanning the 1940s to the 1960s, several medications were developed for the treatment of TB. Streptomycin and P-Aminosalicylic acid (PAS) were among the first drugs introduced during this period, leading to substantial progress in combating the disease.

However, the widespread use of antibiotics also had unintended consequences. The overreliance on single-drug therapy gave rise to the emergence of drug-resistant strains of TB, eventually known as multi-drug resistant TB or MDR-TB. These strains were resistant to the effects of the primary drugs used at the time, posing a significant challenge to TB control efforts.

Fortunately, researchers continued their pursuit of new and more effective treatments. In the 1960s, the introduction of isoniazid, ethambutol, rifampicin, and pyrazinamide brought about a transformative shift in TB treatment. This combination of drugs, known as the first-line TB drugs, proved highly effective, leading to an immediate and sustained decrease in TB incidence worldwide. The success of these medications instilled hope that TB would soon be eradicated as a public health threat.

However, this optimism was short-lived. In the 1980s, TB made an unexpected resurgence, coinciding with the global epidemic of acquired immune deficiency syndrome (AIDS) and the emergence of drug-resistant variants. The HIV/AIDS pandemic weakened immune systems, making individuals more susceptible to TB infection and reactivation. Additionally, drug-resistant TB strains, including extensively drug-resistant TB (XDR-TB), became a grave concern, further complicating TB control efforts.

The re-emergence of TB highlighted the need for renewed efforts in combating the disease. International organizations, governments, and researchers intensified their focus on TB prevention, diagnosis, and treatment. New strategies were implemented, including directly observed therapy (DOT) to ensure medication adherence, improved diagnostic techniques such as molecular testing, and the development of new second-line drugs to combat drug-resistant strains.

Efforts to control TB also extended beyond medical interventions. Socioeconomic factors, including poverty, malnutrition, overcrowding, and limited access to healthcare, played a significant role in the persistence of TB. Addressing these underlying determinants became crucial in comprehensive TB control programs.

In recent years, advancements in TB research have provided hope for improved outcomes. Newer drug regimens, shorter treatment durations, and the development of novel diagnostics have shown promise in enhancing TB management. Furthermore, research into TB vaccines continues, with efforts focused on developing an effective vaccine to prevent TB infection altogether.

While significant progress has been made in the fight against TB, challenges remain. The global burden of TB remains substantial, with millions of new cases and deaths reported each year. Achieving the goal of TB elimination requires continued investment in research, healthcare infrastructure, and collaborative efforts on a global scale. The history of TB serves as a reminder of the complex nature of infectious diseases and the need for sustained vigilance. By learning from the past and adapting strategies to current challenges, it is possible to continue making strides toward a world free from the burden of tuberculosis.

Figure 1. A patient diagnosed with Drug-resistant TB in India

Current treatment options

Treatment for drug-resistant TB depends on the type and severity of the drug resistance, as well as the patient's medical history, age, and overall health status. Currently, there are several treatment options available for drug-resistant TB, including:

1. Conventional Drug Regimens: The standard treatment for drug-resistant TB involves a combination of fluoroquinolones, injectable agents, and other second-line drugs. The treatment duration is longer and more complex than for regular TB, typically lasting between 18 and 24 months.
2. Shorter Treatment Regimens: Recently, new, shorter treatment regimens for drug-resistant TB have been introduced, including a 9-12 month regimen that includes bedaquiline, pretomanid, and linezolid. However, these regimens are still being studied and are not yet widely available.
3. Surgery: In some cases, surgery may be required to remove infected lung tissue or to drain fluid from the lungs.



Figure 2. Thoroughly explains the management of drug-resistant Tuberculosis

Despite these treatment options, drug-resistant TB still poses several limitations and challenges, including:

1. Limited availability of effective drugs: There are only a few drugs available that are effective against drug-resistant TB, and these drugs can have significant side effects.
2. High cost: The cost of treating drug-resistant TB is significantly higher than for regular TB, making it difficult for many patients and health systems to afford.
3. Long duration of treatment: The length of treatment for drug-resistant TB is much longer than for regular TB and can be difficult for patients to complete, leading to treatment failure and the development of further drug resistance.
4. Limited access to care: In many parts of the world, access to diagnosis and treatment for drug-resistant TB is limited, leading to delayed diagnosis and treatment, and further spread of the disease.

In addition to the challenges mentioned, there are other important aspects to consider in the treatment of drug-resistant TB:

Adverse drug reactions: The drugs used to treat drug-resistant TB can cause significant side effects, including nausea, vomiting, hearing loss, liver toxicity, and psychiatric symptoms. These adverse reactions can be challenging to manage and may require close monitoring and supportive care.

Drug interactions: Drug-resistant TB treatment often involves multiple medications, and there can be interactions between these drugs. These interactions can affect the effectiveness of the treatment and may require careful dosage adjustments and monitoring.

Treatment adherence: Ensuring patient adherence to the treatment regimen is crucial for successful outcomes. The long duration of treatment, coupled with the side effects of the medications, can make it challenging for patients to adhere to the prescribed regimen. Healthcare providers must provide education, counseling, and support to help patients understand the importance of completing treatment.

Psychosocial support: Patients with drug-resistant TB may experience psychological and social challenges due to the stigma associated with the disease, the prolonged treatment, and the impact on their daily lives. Psychosocial support, including counseling and support groups, can help patients cope with these challenges and improve their treatment outcomes.

Contact tracing and infection control: Drug-resistant TB is highly contagious, and efforts to prevent its spread are crucial. Contact tracing, identifying individuals who have been in close contact with an infected person, is essential to detect new cases early and initiate appropriate treatment. Additionally, infection control measures, such as isolation and proper ventilation in healthcare facilities, are vital to prevent the transmission of drug-resistant TB.

Research and development: Continued research is needed to develop new and more effective drugs, diagnostic tools, and treatment regimens for drug-resistant TB. This includes investing in the development of novel antibiotics and improving the understanding of the mechanisms of drug resistance to inform future treatment strategies.

Collaboration and global efforts: Addressing the challenges of drug-resistant TB requires international collaboration and coordinated efforts. Governments, healthcare organizations, researchers, and policymakers need to work together to improve access to diagnosis and treatment, strengthen healthcare systems, and develop sustainable strategies to combat drug-resistant TB on a global scale.

In summary, while there are treatment options available for drug-resistant TB, significant challenges remain. Overcoming these challenges requires a comprehensive approach that addresses issues related to drug availability, affordability, treatment adherence, psychosocial support, infection control, and research and development. By addressing these challenges collectively, we can strive to reduce the burden of drug-resistant TB and improve outcomes for patients worldwide.



Figure 3. Flow chart of diagnosis and treatment. MDR-TB, multidrug-resistant tuberculosis; DST, drug susceptibility testing. Created by AU - Zhang, Qing

Prevention

The prevention of drug-resistant TB requires a comprehensive approach that includes various strategies such as screening, contact tracing, and infection control measures. Here are some of the prevention strategies currently used to reduce the incidence of drug-resistant TB:

Screening:

1. Screening is the process of identifying individuals infected with TB, including those who may have drug-resistant strains, in order to provide prompt treatment. Various techniques are used for screening:

- Sputum smear microscopy: This method involves examining a sputum sample under a microscope to detect the presence of TB bacteria. It is a widely available and cost-effective screening method, but it has limitations in detecting drug-resistant strains.
- Nucleic acid amplification testing (NAAT): NAAT is a molecular technique that can detect TB bacteria and determine drug resistance directly from a sputum sample. It provides more accurate and rapid results compared to smear microscopy, particularly for drug-resistant strains.
- Chest X-rays: X-rays can be used to identify abnormalities in the lungs that may indicate TB infection. However, they cannot determine drug resistance and are often used in combination with other screening methods.
- Tuberculin skin tests: These tests involve injecting a small amount of purified protein derivative (PPD) under the skin and evaluating the reaction after a certain period. A positive reaction indicates exposure to TB bacteria, but it does not differentiate between drug-resistant and drug-sensitive strains.

Contact tracing:

2. Contact tracing aims to identify and screen individuals who have been in close contact with TB patients, including those who may have been exposed to drug-resistant strains. This strategy is crucial for interrupting the transmission of TB, particularly in high-risk settings such as prisons, hospitals, and congregate settings. Contact tracing typically involves:

- Identifying close contacts: Health authorities work with TB patients to identify individuals who have had prolonged and close contact with them.
- Screening contacts: Identified contacts are screened for TB infection using similar techniques as mentioned in the screening section. If an active TB case or drug-resistant strain is detected, appropriate treatment is provided to prevent further spread.

Infection control measures:

3. Infection control measures are essential for preventing the transmission of TB, including drug-resistant strains. These measures aim to reduce the risk of TB exposure and include:

- Proper ventilation: Adequate airflow and ventilation systems help dilute and remove infectious droplets containing TB bacteria, reducing the risk of transmission in enclosed spaces.
- Personal protective equipment (PPE): Healthcare workers and individuals in close contact with TB patients should use appropriate PPE, such as masks (respirators), gloves, and eye protection, to minimize the risk of exposure.
- Isolation and quarantine: Patients with active TB, particularly those with drug-resistant strains, should be isolated in well-ventilated rooms or special facilities to prevent transmission to others. Quarantine measures may also be implemented for individuals suspected of having TB until a definitive diagnosis is made.

Improved access to treatment:

4. Ensuring improved access to effective and affordable TB treatment is crucial for preventing the development of drug-resistant strains. Key components of this strategy include:

- Early diagnosis: Prompt diagnosis of TB and drug susceptibility testing help initiate appropriate treatment without delay, reducing the risk of developing drug resistance.

- Access to quality drugs: Access to high-quality, standardized anti-TB medications is essential to ensure effective treatment. This includes both first-line drugs for drug-sensitive TB and second-line drugs for drug-resistant strains.
- Adherence support: Healthcare providers should offer counseling and support to TB patients to promote treatment adherence. Completing the full course of treatment is vital to prevent the development of drug resistance.

Vaccination:

5. Vaccination, specifically with the Bacillus Calmette-Guérin (BCG) vaccine, is a preventive strategy that can reduce the incidence of TB, including drug-resistant strains. The BCG vaccine is primarily given to infants in countries with a high burden of TB. While it is not highly effective in preventing pulmonary TB in adults, it provides some protection against severe forms of TB, such as TB meningitis and disseminated TB in children.

It is important to note that drug-resistant TB prevention requires a multifaceted and integrated approach, combining these strategies with efforts to improve healthcare infrastructure, strengthen diagnostic capabilities, enhance surveillance systems, and promote public awareness about TB and its prevention.



Figure 4. Mechanisms of drug resistance in Mycobacterium tuberculosis by Sarman Singh

Vaccines

Vaccines are an important tool for preventing infectious diseases, and the development of an effective TB vaccine is critical to control the spread of TB, including drug-resistant strains.

The Bacille Calmette-Guérin (BCG) vaccine, developed in the early 1900s, is the only licensed TB vaccine to date. BCG is highly effective in preventing severe forms of TB in children but provides variable protection against adult pulmonary TB. Therefore, the development of a more effective TB vaccine is a research priority.

Several TB vaccine candidates are currently in different phases of clinical trials. These include subunit vaccines, viral vector-based vaccines, and whole-cell inactivated vaccines. These vaccine candidates aim to boost the immune response to TB, and some are designed to target specific aspects of the bacterium's life cycle.

One promising TB vaccine candidate is M72/AS01E, a subunit vaccine that targets the TB antigen 85A. This vaccine has shown efficacy in phase 2b trials, reducing the incidence of pulmonary TB by half in individuals with latent TB infection. Another promising vaccine candidate is VPM1002, a modified BCG vaccine that has shown increased efficacy in preclinical studies and is currently undergoing phase 2 clinical trials.

The potential role of TB vaccines in preventing drug-resistant TB is significant. Vaccines can help prevent the spread of drug-resistant strains by reducing the overall burden of TB in a population. This, in turn, can reduce the selective pressure for the emergence and spread of drug-resistant strains. Furthermore, vaccines may enhance the efficacy of existing TB treatments, reducing the risk of treatment failure and the development of drug resistance.

In conclusion, TB vaccine research is ongoing, with several promising vaccine candidates in different stages of clinical development. The potential role of vaccines in preventing drug-resistant TB is significant and underscores the urgent need for the development of an effective TB vaccine.

Public Interventions

To combat the spread of drug-resistant TB, various public health interventions have been implemented to prevent and treat the disease. These interventions include education campaigns, treatment adherence programs, and patient support services.

1. Education campaigns: Public health education campaigns play a crucial role in raising awareness and promoting the prevention of drug-resistant TB. These campaigns are designed to educate the general public, healthcare workers, and policymakers about the risks of drug-resistant TB, the importance of timely diagnosis and treatment, and ways to prevent the disease from spreading. Education campaigns may include awareness-raising activities such as posters, brochures, and public service announcements on TV and radio.
2. Treatment adherence programs: One of the key factors that contribute to the development of drug-resistant TB is poor adherence to TB treatment. Treatment adherence programs aim to improve treatment outcomes by providing support to patients to help them adhere to their treatment regimens. These programs may include counseling, peer support groups, and directly observed therapy (DOT), where a healthcare worker observes the patient taking their medication.
3. Patient support services: Patients with drug-resistant TB often face a range of challenges, including social stigma, financial difficulties, and psychological distress. Patient support services aim to address these challenges and provide patients with the necessary support to complete their treatment. These services may include social support, nutritional support, and mental health services.

In addition to these interventions, other strategies have been implemented to prevent and control drug-resistant TB. For example, countries have developed guidelines for the management of drug-resistant TB, including the use of appropriate antibiotics, and have strengthened laboratory capacity to facilitate rapid and accurate diagnosis of the disease. There have also been efforts to improve infection control in healthcare facilities to prevent the spread of the disease.

Global efforts

The World Health Organization (WHO) has developed the End TB Strategy to address the global TB epidemic and prevent the spread of DR-TB. The End TB Strategy has three main objectives: to reduce TB deaths by 90% and TB incidence by 80% by 2030, to ensure that no families face catastrophic costs due to TB, and to eliminate all forms of TB, including DR-TB.

To achieve these goals, the End TB Strategy has identified several key interventions, including improving TB detection and diagnosis, providing universal access to TB treatment and care, and investing in TB research and

development. The strategy also emphasizes the need to address the social determinants of TB, such as poverty, malnutrition, and poor living conditions.

In addition to the End TB Strategy, several other international initiatives are aimed at preventing DR-TB. The Global Fund to Fight AIDS, Tuberculosis, and Malaria is a partnership between governments, civil society, and the private sector that aims to accelerate the end of these epidemics. The Global Fund invests in TB programs that focus on early detection and treatment of DR-TB, as well as improving access to TB care for marginalized populations. The Stop TB Partnership is another global initiative that aims to eliminate TB as a public health problem by 2035. The partnership brings together governments, civil society, and international organizations to develop and implement innovative approaches to TB prevention and care. The Stop TB Partnership has prioritized the prevention and treatment of DR-TB as a key component of its strategy.

Finally, the World Health Organization also supports the Green Light Committee, which provides technical assistance and funding to countries to develop and implement programs to prevent and treat DR-TB. The Green Light Committee works with countries to ensure that they have access to high-quality diagnostic tools and effective TB drugs, as well as the resources needed to implement comprehensive DR-TB programs.



Figure 5. Displays the percentage of cases of Drug-Resistant tuberculosis. Created by from World Health Organization. Global tuberculosis report 2018.

Challenges

The challenges that remain in preventing DR-TB include the need for new drugs and diagnostic tools and the importance of addressing social determinants of health. One of the major challenges in preventing DR-TB is the lack of effective treatment options. The current treatment for DR-TB involves a combination of second-line drugs, which are less effective and have more side effects than the standard first-line drugs. Furthermore, the treatment for DR TB is much longer and more expensive than the treatment for drug-susceptible TB. There is an urgent need for new drugs

and treatment regimens that are more effective, less toxic, and shorter in duration. Another challenge is the lack of accurate and rapid diagnostic tools for DR-TB. The current diagnostic tools for TB rely on culture-based methods, which are slow and can take up to six weeks to provide a result. This delay in diagnosis can lead to increased transmission of the disease and poorer treatment outcomes. There is a need for new diagnostic tools that can provide a rapid and accurate diagnosis of DR-TB, particularly in resource-limited settings. Addressing social determinants of health is also crucial in preventing DR-TB. Poverty, overcrowding, malnutrition, and inadequate healthcare systems are all factors that contribute to the spread of TB, including DR-TB. To prevent DR-TB, it is essential to address these underlying social determinants of health.

Future Research Directions

Future research directions that could help to prevent drug-resistant tuberculosis (DR-TB) encompass various areas of investigation. One important avenue of research involves the development of new drugs and treatment regimens to combat DR-TB. The emergence of drug resistance has posed significant challenges to traditional treatment approaches, necessitating the exploration of novel therapeutic options. Researchers are actively working on discovering and developing new antibiotics and antitubercular drugs that can effectively target drug-resistant strains of Mycobacterium tuberculosis, the bacterium that causes TB. These efforts involve screening of chemical libraries, repurposing existing drugs, and exploring new therapeutic targets. Furthermore, the development of new diagnostic tools is crucial in the battle against DR-TB. Rapid and accurate diagnosis of drug resistance is essential for the timely initiation of appropriate treatment, which can prevent further transmission and improve patient outcomes. Researchers are investigating innovative diagnostic techniques, such as molecular assays, next-generation sequencing, and point-of-care testing, to detect drug resistance and guide treatment decisions. These advancements in diagnostics can facilitate early detection of DR-TB cases, enabling targeted interventions and reducing the spread of drug-resistant strains.

Advances in genomics and bioinformatics hold significant promise in unraveling the complex mechanisms underlying DR-TB. By studying the genetic makeup of drug-resistant strains, researchers can gain insights into the genetic mutations and pathways associated with resistance. This knowledge can inform the development of more effective treatments, including novel drug targets and personalized treatment approaches. Additionally, bioinformatics analyses can help identify patterns and predict drug resistance based on genomic data, aiding clinicians in making informed treatment decisions. In addition to biomedical research, it is crucial to investigate the social determinants of health that contribute to the spread of TB, including DR-TB. Factors such as poverty, overcrowding, inadequate healthcare infrastructure, and limited access to quality healthcare can exacerbate the transmission and prevalence of TB, especially drug-resistant forms. Understanding and addressing these social determinants is essential to develop comprehensive strategies for TB control and prevention. Research in this area can provide insights into effective interventions, such as improving living conditions, promoting education and awareness, strengthening healthcare systems, and implementing targeted public health campaigns.

In conclusion, preventing DR-TB necessitates a multifaceted approach that combines advancements in drug development, diagnostic tools, genomics, and addressing social determinants of health. Continued research in these areas is vital to combat the growing threat of drug-resistant strains and reduce the global burden of tuberculosis. By investing in research and implementing evidence-based interventions, we can make significant strides in the fight against DR-TB and improve the health outcomes of individuals affected by this challenging disease.

Conclusion

In conclusion, drug-resistant tuberculosis (TB) is a serious public health concern that requires urgent attention and action. Our research paper has explored various strategies for preventing drug-resistant TB, including early diagnosis and treatment, improved infection control measures, and the development of new drugs and vaccines. It is clear that a

multi-faceted approach is needed to tackle this issue, involving collaboration between healthcare professionals, policymakers, researchers, and affected communities. By implementing these strategies and investing in research and development, we can work towards reducing the burden of drug-resistant TB and improving the health outcomes of those affected by this disease. It is our hope that this research paper will contribute to the ongoing efforts to combat drug-resistant TB and improve global health outcomes.

Acknowledgments

I would first like to thank Josthna Kathar and Dr. Rajagopal Appavu for supporting me and helping me through the journey of this research paper. Coach Jo thoroughly guided me on this research path and helped me narrate this research paper and cleared my queries and Dr. Rajgopal provided me with fantastic detail to further my spectrum on the topic with no doubts. I would also like to thank my student mentor Sashvatkumar for being so generous and helping me find resources to complete this paper. Your guidance and knowledge of antibiotic resistance helped me be able to write this paper. Additionally, I would like to thank my parents for supporting me through this journey. Your love and support are appreciated; I could not have done this without you.

References

CDCTB. (2022, December 20). *Drug-Resistant TB*. Centers for Disease Control and Prevention. https://www.cdc.gov/tb/topic/drtb/default.htm

Edwards, F., MacGowan, A. P., & Macnaughton, E. (2021). *Antibiotic resistance*. *49*(10), 632–637. https://doi.org/10.1016/j.mpmed.2021.07.006

Figure 1. Flow chart of diagnosis and treatment. MDR-TB,... (2015). ResearchGate; ResearchGate. https://www.researchgate.net/figure/Flow-chart-of-diagnosis-and-treatment-MDR-TB-multidrug-resistant-tuberculosis-DST_fig1_288859497

Lange, C., Keertan Dheda, Dumitru Chesov, Mandalakas, A. M., Udwadia, Z. F., & C. Robert Horsburgh. (2019). *Management of drug-resistant tuberculosis*. *394*(10202), 953–966. https://doi.org/10.1016/s0140-6736(19)31882-3

Multi-drug resistant and Extensively drug-resistant TB in India. (n.d.). https://tbcindia.gov.in/WriteReadData/l892s/4252998367Consensus%20statement%20on%20MDR%20XDR%20TB%20-Final(1).pdf

Nguyen, L. (2016). *Antibiotic resistance mechanisms in M. tuberculosis: an update*. *90*(7), 1585–1604. https://doi.org/10.1007/s00204-016-1727-6

Sreeja, M.K.; Gowrishankar, N.L.;Adisha, S.;Divya, K.C. (2014). Antibiotic resistance-reasons and the most common resistant pathogens - A review. *Research Journal of Pharmacy and Technology*, *10*(6), 1886–1890. https://www.indianjournals.com/ijor.aspx?target=ijor:rjpt&volume=10&issue=6&article=054

Swagata Yadavar. (2019, January 10). *Vaishali Shah, Struck By Drug-Resistant TB, Petitioned The PM's Office For A Drug That Saved Her. Others...* IndiaSpend; Indiaspend. https://www.indiaspend.com/vaishali-shah-struck-by-drug-resistant-tb-petitioned-the-pms-office-for-a-drug-that-saved-her-others-died-waiting-for-it/

Tacconelli, E., Carrara, E., Savoldi, A., Stéphan Juergen Harbarth, Mendelson, M., Monnet, D. L., Pulcini, C., Gunnar Kahlmeter, Kluytmans, J., Yehuda Carmeli, Ouellette, M., Outterson, K., Patel, J. B., Cavaleri, M., Cox, E. C., Houchens, C., M Lindsay Grayson, Hansen, P. R., Singh, N., & Theuretzbacher, U. (2017). *Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis*. *18*(3), 318–327. https://doi.org/10.1016/s1473-3099(17)30753-3

Tackling the drug-resistant TB crisis. (2023). Who. int. https://www.who.int/activities/tackling-the-drug-resistant-tb-crisis